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Summary
Background Improving the quality of hospital antibiotic use is a major goal of WHO’s global action plan to combat 
antimicrobial resistance. The WHO Essential Medicines List Access, Watch, and Reserve (AWaRe) classification 
could facilitate simple stewardship interventions that are widely applicable globally. We aimed to present data on 
patterns of paediatric AWaRe antibiotic use that could be used for local and national stewardship interventions.
Methods 1-day point prevalence survey antibiotic prescription data were combined from two independent global 
networks: the Global Antimicrobial Resistance, Prescribing, and Efficacy in Neonates and Children and the Global 
Point Prevalence Survey on Antimicrobial Consumption and Resistance networks. We included hospital inpatients 
aged younger than 19 years receiving at least one antibiotic on the day of the survey. The WHO AWaRe classification 
was used to describe overall antibiotic use as assessed by the variation between use of Access, Watch, and Reserve 
antibiotics, for neonates and children and for the commonest clinical indications.
Findings Of the 23 572 patients included from 56 countries, 18 305 were children (77·7%) and 5267 were neonates 
(22·3%). Access antibiotic use in children ranged from 7·8% (China) to 61·2% (Slovenia) of all antibiotic prescriptions. 
The use of Watch antibiotics in children was highest in Iran (77·3%) and lowest in Finland (23·0%). In neonates, 
Access antibiotic use was highest in Singapore (100·0%) and lowest in China (24·2%). Reserve antibiotic use was low 
in all countries. Major differences in clinical syndrome-specific patterns of AWaRe antibiotic use in lower respiratory 
tract infection and neonatal sepsis were observed between WHO regions and countries.
Interpretation There is substantial global variation in the proportion of AWaRe antibiotics used in hospitalised 
neonates and children. The AWaRe classification could potentially be used as a simple traffic light metric of appropriate 
antibiotic use. Future efforts should focus on developing and evaluating paediatric antibiotic stewardship programmes 
on the basis of the AWaRe index.
Funding GARPEC was funded by the PENTA Foundation. GARPEC-China data collection was funded by the Sanming 
Project of Medicine in Shenzhen (SZSM2015120330). bioMérieux provided unrestricted funding support for the 
Global-PPS.
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Introduction
Antimicrobial resistance is a rapidly emerging global 
public health crisis. In response, the World Health 
Organization has published a global action plan on anti­
microbial resistance,1 one of the aims of which is to 
optimise the use of antimicrobials. Knowledge gaps 
about the global use of antibiotics need to be addressed 
to inform the implementation and monitoring of 
antimicrobial stewardship activities. In 2014, WHO 
recommended improved surveillance of antibiotic use as 
one of its key strategies.2 Children are high users of 
antibiotics, but very little progress has been made 
with developing paediatric antibiotic stewardship 
programmes. One of the difficulties with developing 
such programmes is that the defined daily dose method 
used in adult antibiotic surveillance is not suitable for 
use in neonates and children, who have widely variable 
bodyweights.3,4 In March, 2017, the WHO Essential 
Medicines List (EML) Working Group classified 
antibiotics in the EML for Children (EMLc) into 
three groups: Access, Watch, and Reserve.5 The Access 
group contains generally narrow­spectrum antibiotics 
recommended as first and second choice for most 
common clinical infection syndromes. The Watch group 
contains generally broader spectrum antibiotic classes 
corresponding to the highest priority agents on the list of 
critically important antimicrobial drugs for human 
medicine.6 The Reserve group consists of last­resort 
antibiotics for targeted use in multidrug­resistant 
infections. These groups are collectively known as the 
AWaRe classification,7 and traffic light colour codes have 
been suggested to indicate the different categories: 
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Access antibiotics (green), Watch antibiotics (amber), 
and Reserve antibiotics (red).
Standardised data collection is necessary to better 
understand contemporary antibiotic use among neo­
nates and children worldwide and support the 
development of simple, globally applicable paediatric 
antibiotic steward ship programmes. Data on antibiotic 
use in children are mainly from high­income countries 
(HICs) and remain scarce from low­income and middle­
income countries (LMICs).1 WHO’s global action 
plan highlighted a need for anti microbial resistance 
surveillance networks and centres to collaborate to 
create or strengthen coordinated regional and global 
surveillance.2 In this Article, we report on such a col­
laborative approach, combining paediatric data collected 
in HICs and LMICs from the Global Antimi crobial 
Resistance, Prescribing, and Efficacy in Neonates and 
Children (GARPEC) network and the Global Point 
Prevalence Survey on Antimicrobial Consumption and 
Resistance (Global­PPS) network. Specifically, this study 
aimed to describe antibiotic use in hospitalised neonates 
and children by combining data from the Global­PPS 
and GARPEC networks and establish the feasibility of 
applying the new WHO AWaRe classification to classify 
specific antibiotic use for total and clinical infection 
syndrome in this population.
Methods
Data sources
Data were obtained from the GARPEC and Global­PPS 
networks. Both of these datasets come from point 
prevalence surveys (PPSs) of antibiotic use in hospitalised 
neonates and children. The PPS method has been used 
extensively to measure antimicrobial use in hospitalised 
adults and children.8–10 In both networks, participating 
centres contributed data voluntarily and received no 
financial incentives. This study was considered a clinical 
audit. Each participating hospital received local ethics 
approval if required. All data were anonymised without 
patient identifiers.
Data collection procedures
In 2015, a 1­day pilot PPS was done over 2 months in 
11 countries that were part of the GARPEC network 
Research in context
Evidence before this study
Data on patterns of antibiotic use in the paediatric population 
are mainly from high-income countries, whereas data from 
low-income and middle-income countries are scarce. 
We searched MEDLINE and Embase with the terms “point 
prevalence survey”, “antibiotic”, “pediatric”, “children”, 
and “neonate”, with age restriction (0–18 years) and no 
language restrictions; results were restricted to those published 
before April 14, 2018. A total of 17 relevant articles were 
included, of which one study was done through the European 
Surveillance of Antimicrobial Consumption project, 12 studies 
through the Antimicrobial Resistance and Prescribing in 
European Children network, and two were Indian studies from 
the Global Antimicrobial Resistance, Prescribing and Efficacy in 
Neonates and Children network. One study was done in Italian 
children’s hospitals, collecting data from patients hospitalised 
for more than 48 h by reviewing medical charts. A multicentre 
point prevalence survey (PPS) was done to assess inappropriate 
antibiotic use in hospitalised children in Turkey. These studies 
reported antibiotic prescribing patterns by means of the 
Anatomical Therapeutic Chemical classification. In March, 2017, 
the WHO Essential Medicines List for Children (EMLc) was 
updated and released a new antibiotic classification: Access, 
Watch, and Reserve (known as the AWaRe classification). 
We could identify no previous antibiotic use studies that applied 
the AWaRe classification in the inpatient paediatric population.
Added value of this study
We combined PPS data from three different study groups that 
all used similar methods. We applied the AWaRe classification to 
assess total and condition-specific patterns of antibiotic use for 
neonates and children in the hospital setting. Our study has 
shown the substantial variations of overall AWaRe antibiotics 
use in this population. Previous antibiotic stewardship 
programmes have used the defined daily dose system as the 
main tool to monitor patterns of antibiotic use. However, 
defined daily dose is complex and requires specialist knowledge 
of pharmacological and therapeutic systems. Additionally, 
defined daily dose cannot be applied to measure antibiotic use 
in the paediatric population owing to the wide variation in 
weights in hospitalised children. This study suggests that the 
AWaRe classification might be a simpler metric, and it could 
potentially be used in hospital antibiotic stewardship activities 
to monitor or compare antibiotic use between and within 
hospitals. Furthermore, the AWaRe classification could be a 
simple easy to understand indicator for clinicians and policy 
makers to identify issues of inappropriate antibiotic use and 
develop more specific guidance for antibiotic stewardship 
activities.
Implications of all the available evidence
We have shown that it is feasible to combine global PPSs 
originating from different study partners and subsequently 
categorise both overall and condition-specific patterns of 
antibiotic use by the AWaRe classification. Limitations include 
specific issues with the PPS methodology and the survey being 
biased towards long-stay patients when doing repeated PPS. 
Additionally, antibiotics not listed on the EMLc are not 
classified into an AWaRe category. Further refinement of the 
categories is required to take into account global patterns of 
use and formally evaluate this new method in stewardship 
programmes.
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(Americas: three countries, four hospitals; Africa: 
one country, one hospital; Eastern Mediterranean: 
one country, one hos pital; Europe: two countries, 
two hospitals; Western Pacific: two countries, four 
hospitals; South­East Asia: two countries, three hospitals). 
Following the pilot PPS study, four full­scale 1­day 
GARPEC PPSs were done between February, 2016, and 
February, 2017: February–March, 2016, May–June, 2016, 
September–October, 2016, and December, 2016–February, 
2017. In total, 116 hospitals from 24 countries participated 
in at least one wave of the PPSs between 2015 and 2017 
(Europe: ten countries, 34 hospitals; Americas: three 
countries, 39 hospitals; Western Pacific: five countries, 
25 hospitals; Africa: three countries, five hospitals; 
South­East Asia: two countries, 12 hospitals; Eastern 
Mediterranean: one country, one hospital). Patient 
demo graphics (age, gender, bodyweight), comorbidity, 
anti microbial agents, dose, frequency, route of admin­
istration, empirical or targeted treatment, and reasons for 
treatment were collected. Information on gestational 
age and birthweight were collected for neonates. The 
information collected in the pilot study was similar to 
that of the main waves of PPSs. GARPEC­data were 
collected via REDCap (Research Electronic Data Capture, 
Vanderbilt University, Nashville, TN, USA), a web­
based application through which participating centres 
entered data online. All data were anonymised and linked 
only to an identification number unique to each 
participating centre. Additionally, 31 hospitals in the 
Sharing Anti microbial Reports for Pediatrics Stewardship 
(SHARPS) project—a national antimicrobial stewardship 
collaboration between children’s hospitals in the USA11—
agreed to do a PPS using the GARPEC method and 
contribute their PPS data to the GARPEC network 
between June, 2016, and July, 2017.
A pilot Global­PPS was done between October and 
November, 2014. By means of a standardised surveillance 
method, detailed data on hospitalised adults, neonates, 
and children receiving an antimicrobial on the day 
of the survey were collected between January and 
September, 2015, from 335 hospitals in 53 countries: 
Europe (24 countries; 214 hospitals); Africa (five countries; 
12 hospitals), Asia (16 countries; 57 hospitals), the Americas 
(six countries; 43 hospitals), and Oceania (two countries; 
nine hospitals). A web­based application was used for 
data entry, validation, and reporting designed by the 
University of Antwerp. Further details have been 
published elsewhere.10
We combined the GARPEC­PPS, SHARPS­PPS, and 
Global­PPS paediatric data for analysis. We only present 
variables that were collected in all datasets, including 
patient demographics, antibiotic use (type, route of 
administration, frequency of use), type of treatment (em­
pirical or targeted treatment), and diagnosis. Neonates 
were defined as aged 30 days or younger and children 
were aged between 30 days and younger than 19 years. 
Antibiotic drugs were coded on the basis of the WHO 
Anatomical Therapeutic Chemical (ATC) classification 
system.12 We included antibiotics classified as antibac­
terials for systemic use (ATC code: J01). Prescriptions for 
antifungal (ATC code: J02), antiviral (ATC code: J05), and 
drugs for tuberculosis (ATC code: J04) treatment were 
Figure 1: Regional patterns of AWaRe antibiotic prescribing to children by drug utilisation 90%
AWaRe=Access, Watch, and Reserve. inhib=inhibitor.
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For more on the web-based 
application see 
www.global-pps.com
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excluded, as were antibiotics for topical use. Diagnoses 
were recorded slightly differently in the two datasets and 
were reviewed and unified by a paediatric infectious 
diseases consultant (JB). The mapped diagnoses are 
presented in the appendix.
Antibiotics were classified as Access, Watch, and 
Reserve on the basis of the EMLc (appendix).7 Some 
antibiotics for specific clinical indications are listed by 
WHO in both the Access and Watch groups; these were 
classified as Watch antibiotics in our analyses. Antibiotics 
not included in any of the Access, Watch, and Reserve 
groups were defined as unclassified. This group includes 
all antibiotics not listed on the EMLc such as second-
generation cephalosporins (ATC code: J01DC) and 
combinations of antimicrobials (ATC code: J01RA).
Statistical analysis
Descriptive analyses were done separately for neonates 
and children. We described patterns of antibiotic use 
by using drug utilisation 90%, defined as the number 
of antibiotics that accounted for 90% of the total of 
antibiotics prescribed.13 The proportion of antibiotic 
use in each AWaRe category was calculated as the total 
number of Access, Watch, or Reserve prescriptions 
during the survey divided by the total number of antibiotic 
prescriptions, stratified by country and WHO region.
We then applied the AWaRe classification to treatment 
of the two most common clinical diagnoses, lower 
respiratory tract infection in children and sepsis in 
neonates.8,9 Prescriptions with missing data on patient 
demographics (eg, age and gender) were excluded 
from the analyses. Countries with a total number of 
prescriptions below the 25th percentile were included in 
the analyses but excluded from the graph presentations. 
Data management and analyses were done by means of 
Stata SE software version 14.0.
Role of the funding source
The sponsors of this study had no role in the study 
design, data collection, data analysis, data interpretation, 
or drafting of the manuscript. The corresponding author 
has full access to the final GARPEC dataset and access to 
a subset of completely anonymised Global­PPS data at 
institutional, ward, and patient level. The corresponding 
author has full responsibility for the decision to submit 
for publication.
Results
A total of 23 572 patients were included from 56 countries, 
of whom 18 305 (77·3%) were children and 5267 (22·3%) 
neonates. A full list of included countries and hospitals is 
given in the appendix. The majority of participating 
Figure 2: Regional patterns of AWaRe antibiotic prescribing to neonates by drug utilisation 90% 
AWaRe=Access Watch, and Reserve. inhib=inhibitor.
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Children 
(>1 month)
Neonates 
(≤30 days)
Bacterial lower respiratory tract infection 21·3% 12·5%
Prophylaxis for medical problems 17·0% 8·1%
Prophylaxis for surgical disease 9·4% 6·5%
Other 7·0% 5·2%
Sepsis 6·0% 28·3%
Febrile neutropenia or fever 5·1% ··
Gastrointestinal tract infections 4·9% 4·2%
Skin or soft tissue infections* 4·7% 2·7%
Urinary tract infections 3·8% ··
Upper respiratory tract infections 3·3% ··
Newborn prophylaxis for newborn risk 
factors
·· 12·8%
CNS infections ·· 4·3%
Newborn prophylaxis for maternal risk factors ·· 4·2%
*Includes surgical site infection and burns.
Table: Most frequently reported clinical indications for antibiotic 
prescribing in children and neonates
See Online for appendix
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centres were from HICs (29 of 56), with 19 from upper­
middle­income countries and eight from lower­middle­
income countries. Figure 1 shows the variation between 
WHO regions in antibiotic pre scribing to children. 
Ceftriaxone was the most commonly prescribed antibiotic 
to hospitalised children in Africa, the Eastern Mediter­
ranean, Europe, and South­East Asia. Sulfamethoxazole–
trimethoprim was the most commonly prescribed to 
children in the Americas and azithromycin in the Western 
Pacific region (figure 1). Gentamicin and ampicillin were 
commonly prescribed to hospitalised neonates in most 
regions (Africa, the Americas, the Eastern Mediterranean, 
Europe, and South­East Asia; figure 2). In the Western 
Pacific region, the use of amoxicillin and β­lactamase 
inhibitor, ceftizoxime, and meropenem were high among 
hospitalised neonates (figure 2). Overall, lower respiratory 
tract infection, prophylaxis for medical problems, and 
prophylaxis for surgical disease were the most common 
diagnoses for children receiving antibiotics (table). Sepsis, 
newborn prophylaxis for newborn risk factors, and lower 
respiratory tract infection were the most common 
diagnoses for neonates.
Access group antibiotics Watch group antibiotics Reserve group antibiotics Unclassified antibiotics
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Figure 3: Percentage of total antibiotic use in children by WHO AWaRe classification by country
Only countries with prescriptions >25th percentile are included. AWaRe=Access, Watch, and Reserve.
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Figure 4: Percentage of total antibiotic use in neonates by WHO AWaRe classification by country
Only countries with prescriptions >25th percentile are included. AWaRe=Access, Watch, and Reserve.
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Figure 3 shows the overall percentage of AWaRe 
antibiotics in hospitalised children by country. Slovenia 
had the highest percentage of Access antibiotic use 
(61·2%), followed by Spain (59·8%) and Chile (59·0%). 
China had the lowest percentage of Access antibiotic use 
(7·8%) among the included countries. The percentage of 
Watch antibiotic use in children was high in Iran (77·3%), 
China (74·1%), Montenegro (71·4%), and Macedonia 
(70·4%). The specific Watch drugs used differed between 
these countries (eg, the most commonly prescribed 
Watch antibiotics were ceftriaxone in Iran and azith­
romycin in China). Reserve antibiotics comprised a 
minority of prescriptions in all countries, being highest 
in children in Mexico (20·7%). The Reserve antibiotics 
included mainly the fourth generation cephalosporin 
cefepime to treat lower respiratory tract infection, febrile 
neutropenia, fever, or sepsis. Several countries reported a 
high proportion of unclassified antibiotics use in children; 
this was highest in Finland (60·3%), Georgia (38·3%), 
Latvia (25·0%), and Armenia (22·1%). The most com­
monly used unclassified antibiotics were cefuroxime, 
oxacillin, flucloxacillin, tobramycin, and trimethoprim.
In neonates, Singapore had the highest prevalence of 
Access antibiotic use (100·0%) and China the lowest 
(24·2%; figure 4). Watch antibiotic prescribing to neonates 
was highest in China (64·5%) and no Watch antibiotics 
were reported in Guinea. Compared with Access and 
Watch antibiotics, Reserve antibiotic prescribing was low 
in hospitalised neonates. Russia (13·9%) and Mexico 
(12·8%) reported the highest use of Reserve antibiotics, 
mainly cefepime and daptomycin. Several countries had a 
high proportion of unclassified antibiotic use, including 
Finland (52·6%), Germany (40·2%), Pakistan (35·0%), 
Italy (25·7%), and Canada (21·1%).
Figure 5: Percentage of antibiotic use for children with lower respiratory tract infection
(A) AWaRe classification and WHO region. (B) Percentage of antibiotic use for children with lower respiratory tract infection by AWaRe classification by WHO region 
and country. AWaRe=Access, Watch, and Reserve.
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The percentage of children prescribed Access anti­
biotics for lower respiratory tract infection varied from 
10·3% in the Western Pacific region to 69·7% in Africa 
(figure 5A). The percentage of children with lower 
respiratory tract infection prescribed Watch antibiotics 
varied from 22·9% in Africa to 73·2% in the Western 
Pacific. Variation in AWaRe antibiotic use was also 
observed between countries within the regions 
(figure 5B). In China, the use of Access antibiotics for 
lower respiratory tract infection treatment was very low 
(8·2%) compared with Australia (25·5%) and Japan 
(50·0%) in the Western Pacific region. In Africa, all 
children with lower respiratory tract infection received 
Access antibiotics for treatment in The Gambia. In 
Europe, Russia (5·7%) and Montenegro (5·6%) had the 
lowest percentage of Access antibiotic use; the highest 
percentage of Access antibiotic use was reported in the 
Netherlands (66·7%). Saudi Arabia had the lowest 
percentage of Access antibiotic use (17·7%) in the Eastern 
Mediterranean region. The high use of Watch antibiotics 
for childhood lower respiratory tract infection treatment 
in the Western Pacific region was owing to the high 
proportion of their use in China (76·1%). In the 
Americas, Canada reported a high percentage of Watch 
antibiotic use (61·5%) whereas Mexico had a high use of 
Reserve antibiotics (33·6%). Several European countries 
reported a high proportion of unclassified antibiotics use 
for lower respiratory tract infection treatment in children: 
Georgia (42·0%), Germany (33·3%), Latvia (27·5%), and 
Finland (25·0%).
Europe had the highest use of Access antibiotics (57·1%) 
for neonatal sepsis treatment and the Americas had 
the lowest use (28·6%; figure 6A). The proportion 
of Watch antibiotic use ranged from 35·1% (Europe) 
Figure 6: Percentage of antibiotic use for neonatal sepsis
(A) AWaRe classification and WHO region. (B) Percentage of antibiotic use for neonatal sepsis by AWaRe classification and WHO region and country.  
AWaRe=Access, Watch, and Reserve.
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to 56·1% (Mediterranean). The overall use of Reserve 
antibiotics was low, but was highest in the Americas 
(7·7%). The proportion of unclassified antibiotic use 
for neonates with sepsis was reported to be high in 
the Americas (14·2%) and low in the South­East Asia 
region (0·4%).
In the Americas, Chile reported the highest percentage 
of Access antibiotics (72·2%) and Mexico the lowest 
(50·0%; figure 6B). In the same region, Argentina 
reported high use of Watch antibiotics (42·9%) and 
Brazil the lowest use (16·4%). Mexico reported the 
highest use of Reserve antibiotics for neonatal sepsis 
treatment (16·7%), followed by the USA (2·9%) and 
Brazil (1·0%). In Africa, the use of Access antibiotics 
was low in South Africa (33·3%) and high in Nigeria 
(52·9%). In Ghana, the use of unclassified antibiotics 
was considerable (38·5%) compared with Nigeria (4·0%) 
and South Africa (0·0%). In Europe, Finland had the 
lowest percentage of Access antibiotic use for neonatal 
sepsis treatment (25·0%), mainly owing to the high use 
of unclassified antibiotics (62·5%). Only two European 
countries reported Reserve antibiotic use: Serbia (23·5%) 
and Greece (2·5%). In the South­East Asia region, 
Thailand reported high use of Access antibiotics for 
neonatal sepsis treatment (74·2%), whereas the use was 
lower in India (30·7%). In the Western Pacific region, 
China had the lowest use of Access antibiotics (27·1%) 
and Australia the highest (75·2%).
Discussion
To our knowledge this is the first global collaborative 
study of patterns of antibiotic use in hospitalised children 
that used the WHO AWaRe classification. We have 
observed substantial variation between countries in the 
use of Access, Watch, and Reserve antibiotics in neonates 
and children. In children, Access antibiotic use ranged 
from 7·8% in China to 61·2% in The Gambia; and Watch 
antibiotic use ranged from 23·0% in Finland to 77·3% in 
Iran. There was also substantial variation in patterns of 
antibiotic use for treatment of neonatal sepsis and 
paediatric lower respiratory tract infection.
No recognised standards exist for antibiotic prescribing 
at a population level that would enable us to define 
the appropriateness of antibiotic use for neonates and 
children. Therefore, comparisons between countries 
should be interpreted cautiously. Total amounts of 
antibiotic prescribing are recognised to vary substantially 
between and within countries even across Europe.14 
Important influences are disease burden, including the 
prevalence of infections caused by highly resistant bacteria; 
local health­care service issues (eg, infrastructure, staffing); 
and pricing and affordability of antibiotics. For example, 
the availability of some narrow­spectrum antibiotics, such 
as phenoxymethylpenicillin, is very low in many HIC and 
LMIC countries.15,16 Patterns of antimicrobial resistance 
(particularly for conditions such as sepsis or urinary tract 
infections) are likely to be key drivers, but also difficult 
to identify when defining amounts of appropriate use of 
Access antibiotics. How ever, for some conditions, such as 
childhood lower respiratory tract infection, WHO guidance 
clearly recom mends Access antibiotics (eg, amoxicillin) 
even in countries with high prevalence of pneumococcal 
resistance. Consequently, although opportunities exist to 
incorporate this AWaRe classification within paediatric 
antibiotic stewardship programmes, the situation is clearly 
more complex than simply increasing prescriptions for 
Access antibiotics. It might however be possible in the 
future to combine metrics from several data sources 
to improve estimates of appropriateness of antibiotic 
prescribing in this population.17 A further challenge is that 
several commonly prescribed narrow­spectrum antibiotics 
(eg, second­generation cephalo sporins, trimethoprim) are 
not included in the AWaRe classification as these antibiotics 
are not listed on the EMLc, resulting in a high proportion 
of unclassified antibiotic use for certain countries. The 
EML Working Group acknowledges the limitations of this 
new antibiotic classification and suggests further revision 
over time.7
Other studies have evaluated antibiotic use in children 
at the national or regional level.8,9,18–30 Consistent with 
previous studies, lower respiratory tract infection and 
sepsis were the most common diagnoses in our study 
for children and neonates receiving antibiotics for 
treatment.8,9 We found that the range of antibiotics used is 
much smaller in neonates than in children, which is also 
in line with previous studies.8,9 This might be owing to the 
high use of the two key Access antibiotics, ampicillin and 
gentamicin, in line with the WHO recommendation for 
sepsis treatment in neonates. The most commonly 
prescribed antibiotic in children was ceftriaxone (third-
generation cephalosporin), again in agreement with 
previous studies.8,9 We observed a high proportion of 
Watch antibiotic use in Iranian children in our analysis. 
A multicentre PPS study in Iran has reported high use 
of third-generation antibiotics (ceftriaxone, cefotaxime, 
and ceftazidime) and vancomycin in children.24 The 
consistency of our results with previous studies suggests 
that patterns of use have changed little over time, 
with little evidence of improvement in the quality of 
prescribing.
Several metrics have been developed in support 
of paediatric antibiotic stewardship programme inter­
ventions such as defined daily doses, day of treatment, 
length of treatment, and prescribed daily dose, but all 
of these are quite complex to measure and not easy to 
communicate back to prescribers. The AWaRe classification 
aims to provide an easily interpretable framework for 
broad assessment of patterns of narrow­spectrum and 
broad­spectrum antibiotic use. The patterns of use can be 
derived on the basis of the EMLc guidance for particular 
Access antibiotics for specific clinical conditions.7
The strength of this study lies in the collaboration 
between different research groups combining data, 
thus allowing a wide coverage of countries and regions. 
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The use of a simple, relatively cheap, cross­sectional 
PPS method allowed the collection of data in LMICs, 
where surveillance and stewardship programmes are not 
routinely available. However, although the PPS design has 
been extensively used to evaluate antibiotic use, it has 
some limitations.8–10,20–30 It cannot capture treatment 
duration, switching patterns, or clinical outcomes, and is 
more likely to collect antibiotic data from long­stay 
hospital patients and longer treatment courses. The 
repeated PPS at different time periods might introduce 
bias in the case mix.31 Furthermore, participating centres 
contributed data to the GARPEC and Global­PPS networks 
voluntarily, so our study might not be generalisable to the 
overall inpatient paediatric population. The data collection 
and data entry require clinicians and hospital staff to 
spend time going through medical notes and is clearly 
biased towards larger tertiary academic institutions in 
HICs (only one centre in a low­income country was 
included). Equally importantly, many participating centres 
did not collect data in all their neonatal or paediatric wards 
in their hospitals so the results might not be representative 
within hospitals. Additionally, we have not as yet 
investigated the variation of antibiotic use between 
hospitals in one country, and would not be able on the 
basis of available data to establish whether higher level 
factors, such as hospital infrastructure and resources, 
affect antibiotic use. Thus, more detailed country­specific 
analyses are required to further explore factors that affect 
antibiotic use between tertiary and district hospitals. 
There is also the possibility of an observer effect when 
doing repeated PPSs (GARPEC), whereby participation in 
the study causes changes in prescribing behaviour. 
However, our results were similar to previous studies of 
antibiotic use,8,9 suggesting that any such biases were 
minimal. Finally, there might also be seasonal variations 
in antibiotic use that we have not assesed.32,33
The methods for antibiotic PPSs are now well 
established, whereby countries develop their own online 
tools at national level. However, it has proved easier to 
measure and monitor patterns of antibiotic use than to 
change them. Further work needs to focus on appropriate 
overall amounts of antibiotic use in both the community 
and hospital settings. However, condition-specific 
AWaRE metrics can show, for example, the marked 
variation in the overall proportion of children receiving 
Access antibiotics for lower respiratory tract infection, 
which cannot readily be explained on the basis of WHO 
guidelines. Risk adjustment models therefore need to be 
developed for different clinical conditions, focusing on 
both prevalence of underlying disease (HIV, malnutrition) 
and resistance profiles.34 Furthermore, establishing 
whether the same variation in prescribing patterns 
according to AWaRe categories is also seen in the adult 
population is important. This study has shown that use 
of a simple PPS method is feasible to assess patterns of 
AWaRe antibiotic use in hospitalised children globally. 
National and international ambitions for the proportion 
For more on the National 
Antimicrobial Prescribing 
Survey see https://www.naps.
org.au/Default.aspx
of children in hospital treated with Access antibiotics 
could potentially be assessed by means of the AWaRe 
PPS method.
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